English
Back
Open Account
CSPC PHARMA
wrote a column · Sep 22, 2021 14:43

CSPC launched dasatinib tablets in a big way!

On September 22, International Slow Pill Day, dasatinib tablets (trade name: Apeni) independently developed by CSPC went on sale. “Shining Sword Strikes, Peni Wins Slow Pill”, bringing new choices to slow pill patients. Chronic myeloid leukemia (commonly known as chronic myeloid leukemia, abbreviation CML) is a malignant tumor formed by clonal proliferation of bone marrow hematopoietic stem cells. The commonly used treatment is tyrosine kinase inhibitors (TKI). As a second-generation TKI, dasatinib is a bidirectional kinase inhibitor of BCR-ABL tyrosine kinase and SRC family kinase. It is used to treat adult patients with chronic phase, accelerated phase, and acute phase (acute granulation and rapid progression) of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) who are resistant or intolerant to imatinib mesylate. Dasatinib is a first-line and second-line CML medication recommended by many authoritative guidelines at home and abroad, and can induce faster and deeper relief. CSPC's dasatinib tablets (50mg, 20mg) obtained drug registration approval issued by the State Drug Administration in December 2020, and passed the consistency evaluation for the first time. The launch of Apeni added another powerful weapon to the CSPC Group in treating chronic myeloid leukemia. Dasatinib tablets (ipenil) and imatinib mesylate tablets (nolinine), a subsidiary of CSPC Group, are of high quality and low in price, reducing the financial burden on patients and are beneficial to long-term medication, bringing more choices to patients with slow medication, enabling more patients to survive for a long time, and helping more patients with slow pills to win against sickness...
On September 22, International Slow Pill Day, dasatinib tablets independently developed by CSPC Group (trade name: Epinib) Launched, “Bright Sword Strikes, Penny Wins Slow”, bringing new choices to slow-dose patients.
On September 22, International Slow Pill Day, dasatinib tablets (trade name: Apeni) independently developed by CSPC went on sale. “Shining Sword Strikes, Peni Wins Slow Pill”, bringing new choices to slow pill patients. Chronic myeloid leukemia (commonly known as chronic myeloid leukemia, abbreviation CML) is a malignant tumor formed by clonal proliferation of bone marrow hematopoietic stem cells. The commonly used treatment is tyrosine kinase inhibitors (TKI). As a second-generation TKI, dasatinib is a bidirectional kinase inhibitor of BCR-ABL tyrosine kinase and SRC family kinase. It is used to treat adult patients with chronic phase, accelerated phase, and acute phase (acute granulation and rapid progression) of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) who are resistant or intolerant to imatinib mesylate. Dasatinib is a first-line and second-line CML medication recommended by many authoritative guidelines at home and abroad, and can induce faster and deeper relief. CSPC's dasatinib tablets (50mg, 20mg) obtained drug registration approval issued by the State Drug Administration in December 2020, and passed the consistency evaluation for the first time. The launch of Apeni added another powerful weapon to the CSPC Group in treating chronic myeloid leukemia. Dasatinib tablets (ipenil) and imatinib mesylate tablets (nolinine), a subsidiary of CSPC Group, are of high quality and low in price, reducing the financial burden on patients and are beneficial to long-term medication, bringing more choices to patients with slow medication, enabling more patients to survive for a long time, and helping more patients with slow pills to win against sickness...


Chronic myeloid leukemia (commonly known as chronic myeloid leukemia, abbreviation CML) is a malignant tumor formed by clonal proliferation of bone marrow hematopoietic stem cells. The commonly used treatment is tyrosine kinase inhibitors (TKI).
As a second-generation TKI, dasatinib is a bidirectional kinase inhibitor of BCR-ABL tyrosine kinase and SRC family kinase. It is used to treat adult patients with chronic phase, accelerated phase, and acute phase (acute granulation and rapid progression) of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) who are resistant or intolerant to imatinib mesylate. Dasatinib is a first-line and second-line CML medication recommended by many authoritative guidelines at home and abroad, and can induce faster and deeper relief. CSPC's dasatinib tablets (50mg, 20mg) obtained drug registration approval issued by the State Drug Administration in December 2020, and passed the consistency evaluation for the first time.

On September 22, International Slow Pill Day, dasatinib tablets (trade name: Apeni) independently developed by CSPC went on sale. “Shining Sword Strikes, Peni Wins Slow Pill”, bringing new choices to slow pill patients. Chronic myeloid leukemia (commonly known as chronic myeloid leukemia, abbreviation CML) is a malignant tumor formed by clonal proliferation of bone marrow hematopoietic stem cells. The commonly used treatment is tyrosine kinase inhibitors (TKI). As a second-generation TKI, dasatinib is a bidirectional kinase inhibitor of BCR-ABL tyrosine kinase and SRC family kinase. It is used to treat adult patients with chronic phase, accelerated phase, and acute phase (acute granulation and rapid progression) of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) who are resistant or intolerant to imatinib mesylate. Dasatinib is a first-line and second-line CML medication recommended by many authoritative guidelines at home and abroad, and can induce faster and deeper relief. CSPC's dasatinib tablets (50mg, 20mg) obtained drug registration approval issued by the State Drug Administration in December 2020, and passed the consistency evaluation for the first time. The launch of Apeni added another powerful weapon to the CSPC Group in treating chronic myeloid leukemia. Dasatinib tablets (ipenil) and imatinib mesylate tablets (nolinine), a subsidiary of CSPC Group, are of high quality and low in price, reducing the financial burden on patients and are beneficial to long-term medication, bringing more choices to patients with slow medication, enabling more patients to survive for a long time, and helping more patients with slow pills to win against sickness...


EpernayThe listing has added another powerful weapon for the treatment of chronic myeloid leukemia by the CSPC Group. Dasatinib tablets owned by CSPC Group (Apeni)) and imatinib mesylate tablets (nolinine) High quality and low price, reducing the financial burden on patients is beneficial to long-term medication, bringing more choices to slow-dose patients, enabling more slow-dose patients to survive for a long time, helping more slow-grained patients to win against slow-grained diseases, and making it possible to cure slow-grained diseases. Shiyao Group will use practical actions to carry out the corporate mission of “doing good medicine to repay the world for China”.
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
28K Views
Report
Comments
Write a Comment...